课题基金 / 基金详情

项目摘要

项目成果

RICHARD B DEWEY的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):帕金森病是一种原因不明的不可避免的进行性疾病,其中黑质神经元进行性退化导致大脑多巴胺缺乏症的程度越来越大。虽然已经开发了许多改善神经化学缺陷的治疗方法,但没有任何治疗方法在人类中被证明可以延缓疾病的进展(与掩盖症状不同)。这样的效果是非常理想的,因为如果这可以实现,可以实现患者临床恶化的显著延迟。这项竞争性延续提案旨在继续UT西南医学中心作为正在进行的NET-PD临床试验的临床站点。其中包括正在进行的LS-1研究和FS-ZONE研究。LSI是一项为期5年的双盲、安慰剂对照研究,研究肌酸作为帕金森病可能的疾病调节剂。FS-ZONE是一项为期44周的无效试验,评估吡格列酮作为PD可能的疾病调节剂。
英文摘要
DESCRIPTION (provided by applicant): Parkinson's disease is an inexorably progressive disorder of unknown cause in which neurons of the substantia nigra progressively degenerate resulting in ever greater degrees of brain dopamine deficiency. While a number of treatments have been developed that improve the neurochemical deficit, no treatment has been demonstrated in humans that delays the progression of the disease (as distinguished from masking symptoms). Such an effect is highly desirable because if this could be achieved, a significant delay in clinical deterioration of patients could be realized. This competitive continuation proposal aims to continue UT Southwestern Medical Center as a Clinical Site for ongoing conduct of the NET-PD clinical trials. These include the ongoing LS-1 study and FS-ZONE study. LSI is a 5 year double-blind, placebo controlled investigation of creatine as a possible disease-modifying agent for PD. FS-ZONE is a 44 week futility trial assessing pioglitazone as a possible disease-modifying agent for PD. UT Southwestern Medical Center in Dallas, TX is well suited to continuing its work as a Clinical Site of the NET-PD network. It functions as the primary academic referral center for North Texas, and its four staff neurologists are experienced in the design, conduct, and reporting of clinical trials in Parkinson's disease. If funded, the site will continue its active follow-up of te 49 subjects currently enrolled in the NET-PD LS1 trial and will continue to recruit and follow subjects for the ongoing FS-ZONE study. While it is unclear if either agent under study will slow the progression of PD, this unique network of clinical research centers is ideally suited to perform large scale, long duration, scientifically sound clinical trials that have great promise fo ultimately discovering a drug or drugs that can slow the degenerative process of PD.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
UTSW Clinical Research Site for Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT)
  • 批准号:
    10201768
  • 项目类别:
  • 资助金额:
    $32.4万
  • 财政年份:
    2018
  • 负责人:
    RICHARD B DEWEY
  • 依托单位:
Diagnostic and prognostic biomarkers for Parkinsons disease
  • 批准号:
    8473525
  • 项目类别:
  • 资助金额:
    $64.53万
  • 财政年份:
    2012
  • 负责人:
    RICHARD B DEWEY
  • 依托单位:
Diagnostic and prognostic biomarkers for Parkinsons disease
  • 批准号:
    8554932
  • 项目类别:
  • 资助金额:
    $67.79万
  • 财政年份:
    2012
  • 负责人:
    RICHARD B DEWEY
  • 依托单位:
Diagnostic and prognostic biomarkers for Parkinsons disease
  • 批准号:
    8934186
  • 项目类别:
  • 资助金额:
    $51.54万
  • 财政年份:
    2012
  • 负责人:
    RICHARD B DEWEY
  • 依托单位:
国内基金
海外基金
Sitagliptin通过microbiota-gut-brain轴在2型糖尿病致阿尔茨海默样变中的脑保护作用机制
  • 批准号:
    81801389
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    21.0万元
  • 批准年份:
    2018
  • 负责人:
    田茗源
  • 依托单位:
平扫描数据导引的超低剂量Brain-PCT成像新方法研究
  • 批准号:
    81101046
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    23.0万元
  • 批准年份:
    2011
  • 负责人:
    黄静
  • 依托单位: